

July 21-22, 2025 | Paris, France



Margaret Kabakova, BS, Jessica Mineroff, MD, Jennifer Wang, BS, Raichel Philip, BA, Julia Stolyar, BS, Evan Austin, PhD, MD, and Jared Jagdeo, MD, MS

*SUNY Downstate Health Sciences University,
Brooklyn, NY*

Red, near-infrared, and blue light do not induce DNA damage in human dermal fibroblasts

Abstract: Photobiomodulation (PBM), the use of non-ionizing light to modulate biological activity, is increasingly utilized in dermatology for wound healing, skin rejuvenation, and anti-inflammatory effects. Despite its widespread clinical and consumer use, concerns remain regarding the potential of visible and near-infrared light to induce DNA damage. In this series of in vitro studies, we systematically investigated the genotoxic potential of red (633 ± 6 nm), near-infrared (830 ± 5 nm), and fluorescent blue (417 ± 5 nm) light across a range of clinically relevant and suprathreshold fluences.

Using well-established enzyme-linked immunosorbent assay (ELISA) and DNA immunoblotting, we quantified the formation of cyclobutane pyrimidine dimers (CPDs) and (6-4)- photoproducts (6-4PPs)—two hallmark markers of ultraviolet-induced DNA damage—in human dermal fibroblasts (HDFs) immediately, 3 hours, and 24 hours post-irradiation. Across all wavelengths and fluences tested, no significant induction of CPDs or 6-4PPs was observed relative to matched controls. Ultraviolet-B (UVB) exposure was included as a positive control and consistently induced robust DNA damage.

These findings collectively demonstrate that red, near-infrared, and blue light do not induce measurable DNA damage in HDFs at fluences used in dermatologic practice and home devices. This work provides important preclinical safety data and supports the continued investigation and responsible use of PBM technologies in clinical dermatology. Future studies will be necessary to assess the impact of these wavelengths on other cell types, particularly pigmented or keratinized cells, and to evaluate additional biomarkers of phototoxicity and long-term genomic stability.

July 21-22, 2025 | Paris, France

Keywords: photobiomodulation, cyclobutane pyrimidine dimers, 6-4 photoproducts, DNA damage, human dermal fibroblasts

Biography: Margaret Kabakova is currently a dermatology research fellow and third-year medical student at SUNY Downstate Health Sciences University in Brooklyn, NY. She actively participates in basic science research at the Jagdeo Lab at SUNY Downstate Medical Center and clinical studies at the VA New York Harbor Medical Center – Brooklyn Campus. Previously, Margaret contributed to clinical research at the Pearlmutter Cancer Center NYU Langone Health.

Margaret earned her BS degree from American University in Washington, DC, and subsequently completed a pre-medical post-baccalaureate program at Columbia University in New York, NY.